Medicine pack check sheet

Source-linked reading points

• The archived label lists 25, 100 and 150 mg oral tablets; round, white, biconvex tablets with the respective “T 25,” “T 100” and “T 150” markings are identity clues in this U.S. historical label. Check strength, appearance, package, brand and market together. A difference in any one of them does not establish the same product, authenticity or packaging in another market.
• The label gives a meal-related condition for this exact product and flags medicines affecting gastric acidity, CYP3A4/CYP1A2-related products, smoking and warfarin. Stomach medicines, anti-infectives, herbs, changes in smoking, anticoagulants and every prescription/OTC product should be reviewed with the actual packages by the oncology team or pharmacist; a webpage cannot decide individual co-use, spacing or adjustment.
• Being an EGFR medicine, sharing an mg number or being an oral tablet does not permit self-combination, alternate-day use, conversion from gefitinib/another targeted medicine or a direct pack-to-pack change because of symptoms. Tumour type, molecular testing, prior regimen, organ function and the current target-market label need integrated team review.
• With new or worsening breathing difficulty, cough or fever, persistent or severe diarrhoea, severe rash/blistering, eye pain or vision change, jaundice-like changes, marked bleeding or another acute concern, contact the treatment team promptly or use local urgent medical support. Do not self-pause, restart or change to another EGFR medicine from a webpage.